Preclinical Investigation of the Novel Histone Deacetylase Inhibitor AR-42 in the Treatment of Cancer-Induced Cachexia
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Preclinical Investigation of the Novel Histone Deacetylase Inhibitor AR-42 in the Treatment of Cancer-Induced Cachexia
Authors
Keywords
-
Journal
JNCI-Journal of the National Cancer Institute
Volume 107, Issue 12, Pages djv274
Publisher
Oxford University Press (OUP)
Online
2015-10-14
DOI
10.1093/jnci/djv274
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Disruption of MEF2C signaling and loss of sarcomeric and mitochondrial integrity in cancer-induced skeletal muscle wasting
- (2016) Angie M. Y. Shum et al. Aging-US
- A Rationally Designed Histone Deacetylase Inhibitor with Distinct Antitumor Activity against Ovarian Cancer
- (2015) Ya-Ting Yang et al. NEOPLASIA
- HDAC1 activates FoxO and is both sufficient and required for skeletal muscle atrophy
- (2014) A. W. Beharry et al. JOURNAL OF CELL SCIENCE
- Biochemistry and pathophysiology of intravascular and intracellular lipolysis
- (2013) S. G. Young et al. GENES & DEVELOPMENT
- The role of triglyceride lipases in cancer associated cachexia
- (2013) Suman K. Das et al. TRENDS IN MOLECULAR MEDICINE
- Metabolic derangements in the gastrocnemius and the effect of Compound A therapy in a murine model of cancer cachexia
- (2013) Hirak Der-Torossian et al. Journal of Cachexia Sarcopenia and Muscle
- Abstract 5101: Biomarker identification in non-small cell lung cancer (NSCLC) with activity-based proteomics
- (2012) Thomas Wiedl et al. CANCER RESEARCH
- Cancer Cachexia: Mediators, Signaling, and Metabolic Pathways
- (2012) Kenneth C.H. Fearon et al. Cell Metabolism
- Cellular and molecular mechanisms of muscle atrophy
- (2012) P. Bonaldo et al. Disease Models & Mechanisms
- Current pharmacotherapy options for cancer anorexia and cachexia
- (2012) Antonio Macciò et al. EXPERT OPINION ON PHARMACOTHERAPY
- Acetylation and deacetylation—novel factors in muscle wasting
- (2012) Nima Alamdari et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- p300 Acetyltransferase activity differentially regulates the localization and activity of the FOXO homologues in skeletal muscle
- (2011) Sarah M. Senf et al. AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY
- Inhibition of FoxO transcriptional activity prevents muscle fiber atrophy during cachexia and induces hypertrophy
- (2011) Sarah A. Reed et al. FASEB JOURNAL
- Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes
- (2011) Marcus Bantscheff et al. NATURE BIOTECHNOLOGY
- The role of insulin resistance in the development of muscle wasting during cancer cachexia
- (2011) Mary A. Honors et al. Journal of Cachexia Sarcopenia and Muscle
- Treating cancer cachexia to treat cancer
- (2011) Se-Jin Lee et al. Skeletal Muscle
- Learning to predict cancer-associated skeletal muscle wasting from 1H-NMR profiles of urinary metabolites
- (2010) Roman Eisner et al. Metabolomics
- The Novel Deacetylase Inhibitor AR-42 Demonstrates Pre-Clinical Activity in B-Cell Malignancies In Vitro and In Vivo
- (2010) David M. Lucas et al. PLoS One
- α-Hydroxybutyrate Is an Early Biomarker of Insulin Resistance and Glucose Intolerance in a Nondiabetic Population
- (2010) Walter E. Gall et al. PLoS One
- Cachexia as a major underestimated and unmet medical need: facts and numbers
- (2010) Stephan von Haehling et al. Journal of Cachexia Sarcopenia and Muscle
- Deacetylase Inhibitors Modulate the Myostatin/Follistatin Axis without Improving Cachexia in Tumor-Bearing Mice
- (2009) A. Bonetto et al. CURRENT CANCER DRUG TARGETS
- Evidence for the contribution of insulin resistance to the development of cachexia in tumor-bearing mice
- (2009) Michelle L. Asp et al. INTERNATIONAL JOURNAL OF CANCER
- Histone Deacetylase Inhibitors in Cancer Therapy
- (2009) Andrew A. Lane et al. JOURNAL OF CLINICAL ONCOLOGY
- Mechanisms of Cancer Cachexia
- (2009) Michael J. Tisdale PHYSIOLOGICAL REVIEWS
- OSU-HDAC42, a Histone Deacetylase Inhibitor, Blocks Prostate Tumor Progression in the Transgenic Adenocarcinoma of the Mouse Prostate Model
- (2008) A. M. Sargeant et al. CANCER RESEARCH
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now